Investors·2025-11-03 17:42Core Insights - Pfizer is suing Metsera and Novo Nordisk to block Novo's proposed $6.5 billion acquisition of Metsera, claiming it aims to eliminate competition in the weight-loss market [2][8] - Metsera has labeled Pfizer's claims as "nonsense" and asserts that it will defend its position in court, emphasizing its commitment to shareholders and patients [3][4] - The acquisition is significant for Novo Nordisk as it seeks to mitigate potential sales declines from its leading drugs facing competition and pricing regulations [4] Company Developments - Metsera, an obesity-focused biotech firm, had previously agreed to a $4.9 billion deal with Pfizer before Novo Nordisk's unsolicited bid [1][2] - Pfizer's lawsuit alleges that Metsera breached its obligations under the existing agreement, indicating potential legal complications for the merger [2][5] - Novo Nordisk's primary revenue driver is semaglutide, which is used in weight-loss and diabetes treatments, and acquiring Metsera could enhance its market position [4][5] Market Reactions - Following the news, shares of Pfizer, Novo Nordisk, and Metsera all experienced declines, with Pfizer dropping to $24.59, Novo to $48.90, and Metsera to $61.44 [3]